Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Ghatnekar

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001Ola Ghatnekar, Eva-Lotta Glader
Acta Oncologica (Stockholm, Sweden)|July 10, 2010
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model applicationOla Ghatnekar, Frida Hjalte, Matthew Taylor
Health and Quality of Life Outcomes|March 19, 2013
Mapping health outcome measures from a stroke registry to EQ-5D weightsOla Ghatnekar, Marie Eriksson, Eva-Lotta Glader
BMJ Open|January 15, 2013
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospitalOla Ghatnekar, Asa Bondesson, Ulf Persson, et al.
International Journal of Technology Assessment in Health Care|September 28, 2004
Cost of stroke in Sweden: an incidence estimateOla Ghatnekar, Ulf Persson, Eva-Lotta Glader, et al.
European Journal of Dermatology : EJD|February 25, 2012
Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional studyOla Ghatnekar, Anders Ljungberg, Lars-Erik Wirestrand, et al.
International Journal of Technology Assessment in Health Care|June 5, 2014
Costs for stroke in Sweden 2009 and developments since 1997Ola Ghatnekar, Ulf Persson, Kjell Asplund, et al.
Pharmacoeconomics|December 25, 2010
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in SwedenOla Ghatnekar, Catharina Hjortsberg, Magnus Gisslén, et al.
Oncology and Therapy|March 4, 2026
Exploring Patient Perspectives on Upper Tract Urothelial Cancer: A Qualitative Interview StudyDina Filipenko, Michael Acquadro, Ola Ghatnekar, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 10, 2023
Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims AnalysisNadia Quignot, Heng Jiang, Indraraj Umesh Doobaree, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001Ola Ghatnekar, Eva-Lotta Glader
Acta Oncologica (Stockholm, Sweden)|July 10, 2010
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model applicationOla Ghatnekar, Frida Hjalte, Matthew Taylor
Health and Quality of Life Outcomes|March 19, 2013
Mapping health outcome measures from a stroke registry to EQ-5D weightsOla Ghatnekar, Marie Eriksson, Eva-Lotta Glader
BMJ Open|January 15, 2013
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospitalOla Ghatnekar, Asa Bondesson, Ulf Persson, et al.
International Journal of Technology Assessment in Health Care|September 28, 2004
Cost of stroke in Sweden: an incidence estimateOla Ghatnekar, Ulf Persson, Eva-Lotta Glader, et al.
European Journal of Dermatology : EJD|February 25, 2012
Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional studyOla Ghatnekar, Anders Ljungberg, Lars-Erik Wirestrand, et al.
International Journal of Technology Assessment in Health Care|June 5, 2014
Costs for stroke in Sweden 2009 and developments since 1997Ola Ghatnekar, Ulf Persson, Kjell Asplund, et al.
Pharmacoeconomics|December 25, 2010
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in SwedenOla Ghatnekar, Catharina Hjortsberg, Magnus Gisslén, et al.
Oncology and Therapy|March 4, 2026
Exploring Patient Perspectives on Upper Tract Urothelial Cancer: A Qualitative Interview StudyDina Filipenko, Michael Acquadro, Ola Ghatnekar, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 10, 2023
Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims AnalysisNadia Quignot, Heng Jiang, Indraraj Umesh Doobaree, et al.
Pageof 2